Pityriasis Lichenoides

🧠 Standard of Care & Symptoms

Pityriasis Lichenoides is an uncommon, acquired inflammatory skin disease presenting along a clinical spectrum from acute to chronic forms.

• Clinical Spectrum:
  • Pityriasis Lichenoides et Varioliformis Acuta (PLEVA): Also known as Much-Habermann disease. Presents as sudden crops of itchy, red-brown papules that rapidly develop central necrosis, crusting, and hemorrhage, healing with chickenpox-like scars.
  • Pityriasis Lichenoides Chronica (PLC): Slower, milder eruption of firm, red-brown papules that exhibit a thin, adherent, mica-like ("frosted glass") scale that can be peeled off. Necrosis and scarring are absent.
  • Febrile Ulceronecrotic Much-Habermann Disease (FUMHD): A rare, life-threatening PLEVA variant characterized by large, coalescing necrotic ulcers, high fever, and systemic organ involvement.
• Pathophysiology: The exact etiology is unknown, but it is believed to represent either a hypersensitivity reaction to an infectious agent (such as Epstein-Barr virus, Parvovirus B19, or Toxoplasma gondii) or a benign, clonal T-cell lymphoproliferative process.

🔬 Diagnostics & Interface Histopathology

Clinical history is supported by skin biopsy to differentiate from other lymphoproliferative or infectious eruptions.

• Skin Biopsy: Punch biopsy of an active papule is crucial to confirm diagnosis and rule out cutaneous T-cell lymphoma (such as lymphomatoid papulosis).
• Histopathological Features:
  • PLEVA: Dense, wedge-shaped **dermal lymphocytic infiltrate** that invades the epidermis (interface dermatitis), leading to prominent epidermal necrosis, spongiosis, intraepidermal vesicles, and extravasated red blood cells.
  • PLC: Milder interface dermatitis with superficial perivascular infiltrate, parakeratosis with focal melanin deposits, and minimal to no epidermal necrosis.

CD3/CD8 Immunophenotyping & Clonal T-Cell Assays

Differentiating PLEVA/PLC from malignant cutaneous T-cell lymphoma (CTCL) relies on specific cellular markers:

• Lymphocytic Profiling: Immunohistochemical staining shows that the wedge-shaped infiltrate consists of **CD3+ T lymphocytes**. In PLEVA, cytotoxic **CD8+ T cells** predominate and actively migrate into the epidermis, causing basal layer vacuolization and keratinocyte necrosis. PLC lesions show a more balanced distribution of CD4+ helper T cells and CD8+ cytotoxic T cells in the upper dermis.
• TCR Gene Rearrangement: To rule out Mycosis Fungoides or CTCL, biopsies undergo PCR screening for **T-cell receptor (TCR) beta and gamma gene rearrangements**. While pityriasis lichenoides can sometimes show clonal T-cell populations, the clinical behavior is entirely benign and lacks the progressive malignant features of CTCL.
• Microscopic Signatures: Histological examination shows **extravasated erythrocytes** (red blood cells that have leaked into the skin layers) and focal parakeratosis with blood-filled crusts in PLEVA.

💊 Erythromycin Therapy & Phototherapy

Treatment is directed at reducing inflammation and speeding the resolution of papular crops.

First-Line Oral Antibiotics

• Erythromycin or Tetracyclines (Doxycycline/Minocycline): Prescribed for their anti-inflammatory and immunomodulatory properties rather than antibacterial effects. Used for 1 to 3 months to suppress new lesion formation.

First-Line Phototherapy

• Narrowband UVB (NB-UVB) Phototherapy: Administered 2 to 3 times per week. It suppresses local cutaneous cellular immunity and is highly effective at clearing widespread PLEVA and PLC.

Systemic Therapies (Severe/Refractory Cases)

• Methotrexate or Cyclosporine: Systemic immunosuppressants reserved for severe PLEVA that fails oral antibiotics and phototherapy, or for early-stage FUMHD.

🔬 Active Clinical Trials

Clinical trials are currently evaluating low-dose weekly methotrexate regimens, targeted narrow-band phototherapy dosing protocols, and topical Janus Kinase (JAK) inhibitors.

🗺️ Next Steps After Diagnosis

If you have recently been diagnosed with Pityriasis Lichenoides, implement these care pathways:

1. Obtain a Skin Biopsy: Differentiate PLEVA/PLC from lymphomatoid papulosis via punch biopsy with immunohistochemical staining.
2. Initiate Anti-Inflammatory Antibiotics: Discuss starting a trial of Erythromycin or Doxycycline with your dermatologist for 4-8 weeks.
3. Arrange Phototherapy Sessions: If the rash is widespread, schedule narrowband UVB phototherapy treatments at a local dermatology clinic.
4. Monitor for Systemic Symptoms: Seek immediate medical attention if you develop high fever, throat pain, joint swelling, or rapidly spreading painful ulcers (warning signs of the FUMHD variant).

❓ Patient FAQ

Q: What is the difference between PLEVA and PLC?
A: They are two sides of the same disease spectrum. PLEVA is the acute form, presenting as sudden outbreaks of red-brown bumps that rapidly blister, crust, and bleed, mimicking chickenpox and leaving scars. PLC is the chronic form, presenting as slower, recurrent crops of dry, scaly bumps that do not ulcerate or bleed. PLC spots have a unique "mica-like" scale that flakes off in one piece, and they do not leave scars.

Q: How long does this condition last? Will it ever go away?
A: Pityriasis lichenoides is self-limiting but highly unpredictable. PLEVA usually clears within a few weeks to months, though it can recur in crops. PLC is chronic and can wax and wane for months or even years. Fortunately, both conditions are completely benign (non-cancerous) and eventually resolve permanently in the vast majority of patients.